Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early therapy for Parkinson's disease.

C W Olanow1

  • 1University of South Florida, Tampa 33606.

European Neurology
|January 1, 1992
PubMed
Summary

New Parkinson's disease management considers MAO-B inhibitors for neuroprotection and dopamine agonism to delay levodopa side effects. These strategies aim to improve patient outcomes without sacrificing clinical control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.

Nature aging·2026
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017
Same author

Clinical approaches to the development of a neuroprotective therapy for PD.

Experimental neurology·2017
Same author

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.

Neurobiology of disease·2015
Same author

Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.

Experimental neurology·2009
Same author

Withdrawal of figure 2 from McNaught and Olanow's article, "Proteasome inhibitor-induced model of Parkinson's disease" (Ann Neurol 2006;60:243-247).

Annals of neurology·2009

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Dopamine metabolism generates cytotoxic free radicals, posing a risk in Parkinson's disease.
  • Early Parkinson's disease management requires strategies to mitigate oxidative stress and dopamine toxicity.
  • Chronic levodopa therapy can lead to adverse effects, necessitating early intervention considerations.

Purpose of the Study:

  • To review current management strategies for early Parkinson's disease.
  • To explore the potential neuroprotective role of MAO-B inhibitors.
  • To assess the benefits of early dopamine agonism in delaying levodopa-associated adverse effects.

Main Methods:

  • Literature review of pharmacological interventions for early Parkinson's disease.
  • Analysis of dopamine metabolism and oxidative stress pathways.
  • Evaluation of clinical evidence for MAO-B inhibitors and dopamine agonists.

Main Results:

  • MAO-B inhibitors may offer neuroprotective benefits in early Parkinson's disease.
  • Sustained central dopamine agonism early in treatment may delay adverse effects of long-term levodopa.
  • Management strategies should balance neuroprotection and clinical efficacy.

Conclusions:

  • Early Parkinson's disease treatment should incorporate potential neuroprotective therapies.
  • MAO-B inhibitors and early dopamine agonism are key considerations for optimizing patient management.
  • Future research should focus on refining these strategies for sustained clinical control and neuroprotection.

Related Experiment Videos